What is Biotangents?
Biotangents operates at the intersection of biotechnology and agricultural science, specializing in the development of next-generation molecular diagnostic tools. The company focuses on the livestock industry, providing critical insights that enhance animal welfare, optimize farm productivity, and promote long-term sustainability. By delivering rapid, accurate diagnostic capabilities, Biotangents addresses the urgent need for improved health monitoring in food-producing animals, thereby playing a pivotal role in maintaining the integrity of the global food supply chain. Their proprietary technology is designed to integrate seamlessly into existing veterinary workflows, offering a scalable solution for large-scale agricultural operations.
How much funding has Biotangents raised?
Biotangents has raised a total of $4.4M across 3 funding rounds:
Unspecified
$1.8M
Debt
$1.9M
Unspecified
$743K
Unspecified (2019): $1.8M with participation from Kelvin Capital and Scottish Investment Bank
Debt (2022): $1.9M led by Innovate UK
Unspecified (2022): $743K supported by Scottish Enterprise and Kelvin Capital
Key Investors in Biotangents
Innovate UK
Innovate UK is a non-departmental public body funded by the UK government that provides critical support and grants to high-potential technology and research-driven enterprises.
Kelvin Capital
Kelvin Capital is a prominent investment firm focused on providing growth capital to early-stage and scaling businesses across various high-growth sectors.
Scottish Investment Bank
The Scottish Investment Bank acts as the investment arm of Scottish Enterprise, providing strategic financial support to companies with significant growth potential within the Scottish economy.
What's next for Biotangents?
With this major enterprise-level funding, Biotangents is poised to transition from its current development phase into a broader commercialization strategy. The capital will likely be deployed to scale manufacturing capabilities and expand market reach across international territories where livestock health remains a primary concern. Furthermore, the company is expected to invest heavily in clinical validation studies to solidify its diagnostic efficacy, potentially setting a new benchmark for molecular testing in the animal health market. As the firm continues to refine its product pipeline, it remains a key player to watch for those tracking advancements in agricultural biotechnology and sustainable food production technologies.
See full Biotangents company page
